If Paxlovid Sales Go Private, Pfizer Would Be Free Of Favored-Nation Clause

By John Wilkerson / May 4, 2022 at 3:52 PM
Pfizer executives expect Paxlovid to be approved next year, which would open the coronavirus antiviral to the private market in the United States and potentially free the company of a government requirement to match lower prices negotiated by other rich countries. Other governments are expected to continue buying the drug for their citizens, Pfizer Chair and CEO Albert Bourla said Tuesday (May 3). The U.S. government bought 10 million courses of Paxlovid, currently authorized for emergency use, at $5.3 billion,...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.